Next Article in Journal
Human Poisoning from Marine Toxins: Unknowns for Optimal Consumer Protection
Next Article in Special Issue
Pharmacokinetic Properties of the Nephrotoxin Orellanine in Rats
Previous Article in Journal
Effects of Heme Modulation on Ovophis and Trimeresurus Venom Activity in Human Plasma
Previous Article in Special Issue
Biological Activities of Cationicity-Enhanced and Hydrophobicity-Optimized Analogues of an Antimicrobial Peptide, Dermaseptin-PS3, from the Skin Secretion of Phyllomedusa sauvagii
Article Menu
Issue 8 (August) cover image

Export Article

Open AccessReview
Toxins 2018, 10(8), 323; https://doi.org/10.3390/toxins10080323

Bouganin, an Attractive Weapon for Immunotoxins

Department of Experimental, Diagnostic and Specialty Medicine-DIMES, General Pathology Section, Alma Mater Studiorum—University of Bologna, Via S. Giacomo 14, 40126 Bologna, Italy
*
Author to whom correspondence should be addressed.
Received: 18 July 2018 / Revised: 27 July 2018 / Accepted: 2 August 2018 / Published: 8 August 2018
(This article belongs to the Special Issue Venom and Toxin as Targeted Therapy)
Full-Text   |   PDF [942 KB, uploaded 8 August 2018]   |  

Abstract

Bougainvillea (Bougainvillea spectabilis Willd.) is a plant widely used in folk medicine and many extracts from different tissues of this plant have been employed against several pathologies. The observation that leaf extracts of Bougainvillea possess antiviral properties led to the purification and characterization of a protein, named bouganin, which exhibits typical characteristics of type 1 ribosome-inactivating proteins (RIPs). Beyond that, bouganin has some peculiarities, such as a higher activity on DNA with respect to ribosomal RNA, low systemic toxicity, and immunological properties quite different than other RIPs. The sequencing of bouganin and the knowledge of its three-dimensional structure allowed to obtain a not immunogenic mutant of bouganin. These features make bouganin a very attractive tool as a component of immunotoxins (ITs), chimeric proteins obtained by linking a toxin to a carrier molecule. Bouganin-containing ITs showed very promising results in the experimental treatment of both hematological and solid tumors, and one bouganin-containing IT has entered Phase I clinical trial. In this review, we summarize the milestones of the research on bouganin such as bouganin chemico-physical characteristics, the structural properties and de-immunization studies. In addition, the in vitro and in vivo results obtained with bouganin-containing ITs are summarized. View Full-Text
Keywords: antiviral activity; Bougainvillea; bouganin; cancer therapy; immunotherapy; immunotoxins; ribosome-inactivating proteins; rRNA N-glycosylase activity; VB6-845 antiviral activity; Bougainvillea; bouganin; cancer therapy; immunotherapy; immunotoxins; ribosome-inactivating proteins; rRNA N-glycosylase activity; VB6-845
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Bortolotti, M.; Bolognesi, A.; Polito, L. Bouganin, an Attractive Weapon for Immunotoxins. Toxins 2018, 10, 323.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top